aratinga.bio

aratinga.bio was a preclinical-stage immunotherapy biotech focused on developing novel cancer treatments based on an in vivo CAR-T platform. The company aimed to create therapies effective in both hematological malignancies and solid tumors, with a strategy that combined gene transfer, nucleotide-based approaches, and polymeric nanoparticle-related technology. Founded in 2017 in France, the company built capabilities around CAR-T development and bioproduction near the Gustave Roussy cancer cluster in Villejuif. In June 2020, Rexgenero acquired aratinga.bio SAS Group's key technology, program assets, intellectual property, license rights, facilities, and team, so aratinga.bio no longer appears to operate as an independent active company.